Alumis Advances Envudeucitinib Toward Phase 3 in SLE
SAN FRANCISCO, Sept. 1, 2026 Alumis Inc. announced topline results from its Phase 2b LUMUS trial of envudeucitinib in...
systemic lupus erythematosus
Advertisement
Adicet Bio Advances Prula-Cel Toward SLE Data Readout
REDWOOD CITY, Calif., September 1, 2026 Adicet Bio announced completion of the last patient visit for the planned Phase...
Lupus Foundation Awards Grants to Advance Targeted Research
New York and Massachusetts, USA, August 14, 2026 The Lupus Foundation of America has announced the recipients of its...
Fate Therapeutics Advances FT819 in Lupus Nephritis
San Diego, California — August 14, 2026 Fate Therapeutics, Inc. has initiated the potentially registrational RECLAIM-LN Phase 2 clinical...
Neutrolis Reports First Human NET-Degrading Therapy Evidence
CAMBRIDGE, Mass., July 15, 2026 Neutrolis announced the publication of a clinical report in the New England Journal of...
Advertisements
Keenova Publishes New Real-World Acthar Gel Autoimmune Data
DUBLIN, Ireland, July 13, 2026 Keenova Therapeutics plc has announced the publication of a new peer-reviewed real-world evidence study...
Imviva Biotech Advances CTA313 CAR-T Program with FDA IND Approval
BOSTON, June 9, 2026 Imviva Biotech announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational...
Novartis Highlights Immunology Pipeline Progress at EULAR 2026
BASEL, Switzerland, June 1, 2026 Novartis announced that it will present new data from 31 abstracts across its expanding...
InnoCare Wins China NDA Acceptance for Orelabrutinib in ITP
BEIJING — May 28, 2026 InnoCare Pharma announced that China’s Center for Drug Evaluation (CDE) under the National Medical...
Roche’s Gazyva Moves Closer to Public Access in Canada for Lupus Nephritis
MISSISSAUGA, Ontario, May 22, 2026 Roche Canada announced that Canada’s Drug Agency (CDA-AMC) has issued a positive reimbursement recommendation...
Advertisement
